Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - okedi
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp3a36f8c3c4c534a765e5e9ed08db5433
identifier: http://ema.europa.eu/identifier
/EU/1/21/1621/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: OKEDI 75 mg powder and solvent for prolonged-release suspension for injection
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-3a36f8c3c4c534a765e5e9ed08db5433
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/21/1621/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - okedi
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
OKEDI contains the active substance risperidone which belongs to the group of medicines called antipsychotics .
OKEDI is used in adult patients to treat schizophrenia, where you may see, hear or feel things that are not there, believe things that are not true or feel unusually suspicious, or confused.
OKEDI is intended for patients who show tolerability and effectiveness to oral (e.g. tablets) risperidone.
OKEDI can help alleviate the symptoms of your disease and stop your symptoms from coming back.
Do not use OKEDI:
Warnings and precautions Talk to your doctor or pharmacist before taking OKEDI if:
Children and adolescents
Do not give this medicine to children and adolescents under 18 years old. Other medicines and OKEDI Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. It is especially important to talk to your doctor or pharmacist if you are taking any of the following
You will be given OKEDI as an intramuscular injection either in the upper arm or buttock every 28 days, by a healthcare professional. Injections should be alternated between the right and left sides.
The recommended dose is 75 mg every 28 days, but a higher dose of 100 mg every 28 days may be necessary. Your doctor will decide on the dose of OKEDI that is right for you.
If you are currently treated with other antipsychotics than risperidone, but have taken risperidone in the past, you should begin taking oral risperidone with at least 6 days before beginning treatment with OKEDI.
If you have never taken any form of risperidone, you should begin taking oral risperidone with at least 14 days before beginning treatment with OKEDI. The duration of the oral risperidone period will be determined by your physician.
If you have kidney problems OKEDI is not recommended in patients with moderate to severe impaired kidney function. If you are given more OKEDI than you should
If you stop using OKEDI You will lose the effects of the medicine. You should not stop using this medicine unless told to do so by your doctor as your symptoms may return.
It is important not to miss your appointments when you are supposed to receive your injections of this medicine once every 28 days. If you cannot keep your appointment, make sure to contact your doctor right away to discuss another date when you can come in for your injection.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. Contact a doctor or go to your nearest emergency department immediately if you experience the following uncommon side effect (may affect up to 1 in 100 people):
Uncommon side effects (may affect up to 1 in 100 people):
Rare side effects (may affect up to 1 in 1,000 people):
Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton, aluminium pouches or syringe labels after (EXP). The expiry date refers to the last day of that month. Store below 30 C. Store in the original package in order to protect from moisture. Use OKEDI immediately after reconstitution.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What OKEDI contains The active substance is risperidone.
Only the powder syringe contains the active substance. Once reconstituted the amount of risperidone delivered is 75 mg.
The other ingredients are:
Pre-filled syringe of powder: poly-(D, L-lactide-co-glycolide).
Pre-filled syringe of solvent: dimethyl sulfoxide.
What OKEDI looks like and contents of the pack Each kit box of OKEDI powder and solvent for prolonged-release suspension for injection contains: An aluminium pouch with one pre-filled syringe containing powder (within this powder is the active substance, risperidone) and a silica gel desiccant sachet. The powder is white to white- yellowish, non-aggregated. An aluminium pouch with one pre-filled syringe containing the solvent and a silica gel desiccant sachet. The pre-filled syringe of the solvent contains a clear solution and has a RED finger flange. One sterile needle for IM injection 2 inch (0.90 x 51mm [20G]) with safety shield used for gluteus administration. One sterile needle for IM injection 1 inch (0.80 x 25mm [21G]) with safety shield used for deltoid administration.
Marketing Authorisation Holder and Manufacturer Laboratorios Farmac uticos Rovi, S.A. Juli n Camarillo, 28037 Madrid. Spain
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:
Belgi /Belgique/Belgien Laboratorios Farmac uticos Rovi, S.A. Juli n Camarillo, 28037 Madrid Espagne/Spanje Tel: +34 91 375 62 Lietuva Laboratorios Farmac uticos Rovi, S.A. Juli n Camarillo, 28037 Madrid Ispanija Tel: +34 91 375 62
Laboratorios Farmac uticos Rovi, S.A. Juli n Camarillo, 28037 Madrid
Te .: +34 91 375 62 Luxembourg/Luxemburg Laboratorios Farmac uticos Rovi, S.A. Juli n Camarillo, 28037 Madrid Espagne/Spanien Tel: +34 91 375 62 esk republika Laboratorios Farmac uticos Rovi, S.A. Juli n Camarillo, 28037 Madrid pan lsko Tel: +34 91 375 62 Magyarorsz g Laboratorios Farmac uticos Rovi, S.A. Juli n Camarillo, 28037 Madrid Spanyolorsz g Tel: +34 91 375 62 Danmark Laboratorios Farmac uticos Rovi, S.A. Juli n Camarillo, 28037 Madrid Spanien Tlf: +34 91 375 62 Malta Laboratorios Farmac uticos Rovi, S.A. Juli n Camarillo, 28037 Madrid Spanja Tel: +34 91 375 62 Deutschland Rovi GmbH Rudolf-Diesel-Ring 6 83607 Holzkirchen Tel: +49 8024 4782Nederland Laboratorios Farmac uticos Rovi, S.A. Juli n Camarillo, 28037 Madrid Spanje Tel: +34 91 375 62 Eesti Laboratorios Farmac uticos Rovi, S.A. Juli n Camarillo, 28037 Madrid Hispaania Tel: +34 91 375 62 Norge Laboratorios Farmac uticos Rovi, S.A. Juli n Camarillo, 28037 Madrid Spania Tlf: +34 91 375 62
BIANE . . 8, 14671 . ,
T . 210 8009 sterreich Rovi GmbH Rudolf-Diesel-Ring 6 83607 Holzkirchen Deutschland Tel: +43 664 1340Espa a Laboratorios Farmac uticos Rovi, S.A. Juli n Camarillo, 28037 Madrid Tel: +34 91 375 62 Polska Laboratorios Farmac uticos Rovi, S.A. Juli n Camarillo, 28037 Madrid Hiszpania Tel: +34 91 375 62 France ROVI
24, Rue Du Drac
38180 Seyssins T l: +33 (0)4 76 968 Portugal Laboratorios Farmac uticos Rovi, S.A. Juli n Camarillo, 28037 Madrid Espanha Tel: +34 91 375 62 Hrvatska Laboratorios Farmac uticos Rovi, S.A. Juli n Camarillo, 28037 Madrid panija Tel: +34 91 375 62 Rom nia Laboratorios Farmac uticos Rovi, S.A. Juli n Camarillo, 28037 Madrid Spania Tel: +34 91 375 62 Ireland Laboratorios Farmac uticos Rovi, S.A. Juli n Camarillo, 28037 Madrid Spain Tel: +34 91 375 62 Slovenija Laboratorios Farmac uticos Rovi, S.A. Juli n Camarillo, 28037 Madrid panija Tel: +34 91 375 62 sland Laboratorios Farmac uticos Rovi, S.A. Juli n Camarillo, 28037 Madrid Sp nn S mi: +34 91 375 62 Slovensk republika Laboratorios Farmac uticos Rovi, S.A. Juli n Camarillo, 28037 Madrid panielsko Tel: +34 91 375 62 Italia Rovi Biotech, S.R.L. Viale Achille Papa, 20149 Milano Tel: +39 02 366 877 Suomi/Finland Laboratorios Farmac uticos Rovi, S.A. Juli n Camarillo, 28037 Madrid Espanja/Spanien Puh/Tel: +34 91 375 62
Laboratorios Farmac uticos Rovi, S.A. Juli n Camarillo, 28037 Madrid
: +34 91 375 62 Sverige Laboratorios Farmac uticos Rovi, S.A. Juli n Camarillo, 28037 Madrid Spanien Tel: +34 91 375 62 Latvija Laboratorios Farmac uticos Rovi, S.A. Juli n Camarillo, 28037 Madrid Sp nija Tel: +34 91 375 62 United Kingdom (Northern Ireland) Rovi Biotech Limited
Davis House 4th Floor Suite Robert Street Croydon CR0 1QQ - UK Tel: + 44 (0) 203 642 06 This leaflet was last revised in MM/YYYY. The following information is intended for healthcare professionals only INSTRUCTIONS FOR HEALTHCARE PROFESSIONALS OKEDI 75 mg powder and solvent for prolonged-release suspension for injection
Important information
OKEDI requires close attention to these step-by-step Instructions for Use to help ensure successful administration.
Use components provided The components in the kit box are specifically designed for use with OKEDI.
OKEDI must be reconstituted only with the solvent supplied in the kit box.
Do not substitute ANY components of the kit box.
Administer dose immediately after reconstitution. For intramuscular use only after reconstitution.
Proper dosing
The entire content of the reconstituted syringe must be administered to ensure intended dose of OKEDI is delivered.
Single use device
Working on a clean surface, open the sachets and discard the desiccant pack.
The kit box of OKEDI contains:
One aluminium foil pouch with a OKEDI pre-filled syringe with a WHITE plunger rod and WHITE finger flange. The syringe is marked with . One aluminium foil pouch with SOLVENT for OKEDI pre-filled syringe with a TRANSPARENT plunger rod and a RED finger flange. The syringe is marked with . Two administration needles (21G, 1 inch for deltoid [green cap] and a 20G, 2 inch for gluteus [yellow cap]).
Discard the kit if any component is damaged.
In the event of any foreign particulate matter and/or variation of physical aspect is observed, do not administer OKEDI.
1.1 Inspect solvent syringe
ENSURE that SOLVENT syringe content flows normally as a liquid.
The solvent freezes below 19 C. If it is frozen or partially frozen, allow to thaw using hands contact or leaving it at room temperature until liquid flow recovered before continuing.
1.2 Dislodge powder syringe
TAP the OKEDI syringe to dislodge potential packed powder near the cap.
2.1 Uncap syringes in upright position
Hold both syringes in upright position to prevent loss of product.
PULL the cap off the Solvent syringe.
TWIST and PULL the Powder syringe cap off.
2.2 Connect the syringes Pick the solvent syringe S that has the coloured finger flange and place it on TOP of the powder syringe R, or slightly lean it when connecting. TWIST the syringes together until you feel a slight resistance.
Make sure that Powder syringe R is in the upright position to prevent loss of product.
STOP AND READ THIS SECTION BEFORE STARTING OR THE MEDICINE MAY NOT CORRECTLY RECONSTITUTE.
PUSH VIGOROUSLY the Solvent content towards the Powder syringe.
DO NOT WAIT for powder wetting and QUICKLY start mixing contents by pushing the plungers FAST and alternately for 100 pushes (2 pushes within 1 second, approximately 1 minute).
ENSURE medicine is passing between both syringes for a properly mixing: medicine is viscous and you will need to apply force when pressing on the plunger rods.
Mix for at least 100 pushes by doing alternately
followed by
Make sure medicine is passing between both syringes
When medicine is correctly mixed, the appearance will be a uniform suspension off white to yellowish colour and thick consistency.
Once reconstituted, proceed immediately to prepare the injection syringe for administration to avoid loss of homogeneity.
4.1 Transfer medicine
Place downward pressure on the R plunger rod and transfer all the content into the S syringe that has attached the coloured finger flange.
Make sure all the content is transferred.
4.2 Detach syringes Once the medicine is fully transferred, separate the two syringes by untwisting.
OKEDI should be administered immediately to avoid loss of homogeneity.
4.3 Attach the sterile needle with safety shield Choose the proper needle:
Deltoid: 21G, 1 inch for deltoid (green cap).
Gluteus: 20G, 2 inch for gluteus (yellow cap).
Attach it using a clockwise twisting motion. Do not over-tighten. 4.4 Remove exceeding air
Remove needle cover and push out the excess of air (only big bubbles) from the syringe barrel.
DO NOT expel any drops of medicine
If medicine is seen at the needle tip, pull back slightly on the plunger to prevent medicine spillage.
5.1 Inject medicine
Insert the needle fully into the muscle. DO NOT INJECT BY ANY OTHER ROUTE.
THICK MEDICINE, INJECT IT SLOWLY AND STEADILY. MAKE SURE TO FULLY INJECT IT. The injection time is longer than usual due to the viscosity of the medicine. Wait a few seconds before removing the needle. Avoid inadvertent injection into a blood vessel.
5.2 Dispose medicine Cover the needle pressing on the needle guard using a finger or a flat surface and dispose immediately in a secure sharps disposal container.
Package leaflet: Information for the user
OKEDI 100 mg powder and solvent for prolonged-release suspension for injection risperidone Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Entry 1 - fullUrl = Composition/composition-en-3a36f8c3c4c534a765e5e9ed08db5433
Resource Composition:
Generated Narrative: Composition composition-en-3a36f8c3c4c534a765e5e9ed08db5433
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/21/1621/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - okedi
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp3a36f8c3c4c534a765e5e9ed08db5433
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp3a36f8c3c4c534a765e5e9ed08db5433
identifier:
http://ema.europa.eu/identifier
/EU/1/21/1621/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: OKEDI 75 mg powder and solvent for prolonged-release suspension for injection
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en